Aubrey de Grey and the Claim That Someone Alive Will Live 1,000 Years

Facebook ↗WhatsApp ↗
Aubrey de Grey Says the First Person to Live 1,000 Years May Be Alive

Aubrey de Grey, an English biomedical gerontologist, has argued for years that ageing is a set of damage processes that medicine can learn to repair, and that the first person who will live to 1,000 may already have been born. He made that claim in a 2008 broadcast on the European channel Arte, suggesting the person might then be in their 50s or 60s. It is a bold forecast, not a finding: no therapy has yet been shown to extend human lifespan, and many ageing researchers think his timeline is far too optimistic. Here is what he proposes, why it is controversial, and what the debate looks like now.

Who Aubrey de Grey is

De Grey was born in London in 1963. He studied computer science at Trinity Hall, Cambridge, graduating in 1985, and from 1992 to 2006 led software development for FlyBase, a genetic database for fruit-fly research, in Cambridge University's Genetics Department. In 2000 Cambridge awarded him a PhD in biology by publication, based on his work on the role of mitochondria in ageing. Popular articles often called him a "Cambridge geneticist," but his formal training was in computing, and his ageing work began largely outside a laboratory.

In 2003 he co-founded the Methuselah Foundation, known for the Methuselah Mouse Prize for record lifespan extension in mice. In 2009 he co-founded the SENS Research Foundation in California and served as its chief science officer until 2021. Since 2022 he has led the Longevity Escape Velocity (LEV) Foundation as president and chief science officer.

The idea: treat ageing like a repair job

De Grey's programme is called SENS, short for Strategies for Engineered Negligible Senescence. Instead of trying to slow the metabolism that slowly damages the body, he argues for periodically repairing the damage itself, much as a vintage car can run for a century if worn parts are regularly fixed. SENS groups that damage into categories, among them cell loss, cells that should die but do not, mutations in mitochondria and the cell nucleus, junk that builds up inside and outside cells, and stiffening of tissues.

The 1,000-year figure comes from a further idea he calls "longevity escape velocity." If each round of therapies bought people enough extra healthy years for scientists to develop the next, better round, the remaining life expectancy of someone receiving them would keep rising faster than time passes. In that scenario, death from ageing would become rare, and the main causes of death would be accidents, violence and infections. The 1,000-year number is not a calculation from data; it is an illustration of where that logic leads if every step works.

Why many scientists are sceptical

The pushback started early. In 2005, 28 researchers wrote in EMBO Reports that none of de Grey's proposed interventions had been shown to extend the lifespan of any organism, let alone humans. The same year, MIT Technology Review and the Methuselah Foundation offered $20,000 to any molecular biologist who could show SENS was so wrong it did not deserve serious debate. A panel including Craig Venter and Nathan Myhrvold judged that no entrant had met that bar, but added a balanced verdict: "SENS does not compel the assent of many knowledgeable scientists; but neither is it demonstrably wrong."

The surgeon and author Sherwin Nuland, who taught at Yale, profiled de Grey for Technology Review in February 2005. He found him likeable and brilliant, but argued that none of the problems SENS identifies had been solved, that the body is too interdependent for a parts-replacement approach, and that the project would change society in unpredictable ways. Other critics point out that several SENS strategies, such as engineering copies of mitochondrial genes into the cell nucleus or removing telomerase from the whole body, are enormously difficult, and that the body's systems interact in ways that make repairing one kind of damage at a time harder than the car analogy suggests.

It is fair to say that the field has moved closer to some of de Grey's themes since 2005. Research on senolytics (drugs that clear ageing "zombie" cells) and on partial cellular reprogramming has attracted large investments, and companies such as Google's Calico were founded to study the biology of ageing. But results so far come mainly from cells and animals, and none has shown that people can live beyond the documented record of 122 years.

How research into ageing is funded

Ageing research is not a fringe pursuit. In the United States the National Institute on Aging, part of the National Institutes of Health, funds work on the basic biology of ageing alongside research on dementia and the health of older adults. Much of the money for more radical life-extension projects, however, comes from private donors and technology entrepreneurs, which is one reason the field attracts both enthusiasm and suspicion.

Politics has shaped the field too. In 2001 President George W. Bush limited federal funding for human embryonic stem cell research to cell lines that already existed, a decision driven by ethical objections to destroying embryos. Some life-extension advocates saw this as a brake on regenerative medicine; the policy was loosened in 2009. Claims that such decisions were secretly aimed at blocking a "fountain of youth" are speculation, not documented fact.

The overpopulation question and other objections

The first objection most people raise is crowding: if nobody died of old age, where would everyone live? De Grey's answer has been that people who expect to live much longer would likely have fewer children and later, and that societies would adapt over the decades such therapies would take to spread. Some enthusiasts go further and mention space settlement, which remains far beyond present technology.

Demographers note that birth rates in most of the world have already fallen sharply, and that global population is projected to peak and then decline later this century. Even so, radical life extension would raise serious questions about pensions, jobs, inequality (who could afford the treatments first?) and how generations share power. These are good reasons to debate the idea openly, whatever one thinks of its scientific prospects.

Controversy and where things stand

De Grey's career took a turn in 2021. In August the SENS Research Foundation put him on leave after two women made sexual harassment allegations. An independent investigator found that he had made inappropriate remarks to the two women, did not substantiate various other allegations, and concluded that his attempt to contact one of the complainants through a third party amounted to interference with the inquiry. He was removed as chief science officer. The following year he launched the LEV Foundation, which has funded a large mouse study testing several rejuvenation interventions in combination.

For readers, the practical takeaway is simple. Healthy-lifespan research is real and worth following, but no product or supplement today can reverse ageing, and claims to the contrary should be treated with caution. The most reliable ways to add healthy years remain the familiar ones: not smoking, staying active, sleeping well, eating a varied diet and keeping up with health checks. For anything specific to your own health, talk to a doctor.

Would living for centuries be a gift? Many of us think of unread books and unvisited places and feel the pull. Others worry that a life without an end would lose some of its meaning. De Grey's great achievement may be that he forced that question out of science fiction and into serious discussion.

Sources: Wikipedia: Aubrey de Grey (biography, SENS challenge verdict, EMBO Reports letter, 2021 investigation); MIT Technology Review: Do You Want to Live Forever?; first shared via The Mind Unleashed.

COMMENTS